BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24927263)

  • 1. Targeted therapies for treatment of recurrent ovarian cancer.
    Grisham RN; Hyman DM; Iyer G
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer relapse: From the latest scientific evidence to the best practice.
    Luvero D; Plotti F; Aloisia A; Montera R; Terranova C; Carlo De Cicco Nardone ; Scaletta G; Lopez S; Miranda A; Capriglione S; Gatti A; Pierluigi Benedetti Panici ; Angioli R
    Crit Rev Oncol Hematol; 2019 Aug; 140():28-38. PubMed ID: 31176270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in ovarian cancer.
    Lim HJ; Ledger W
    Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents in epithelial ovarian cancer.
    See HT; Kavanagh JJ
    Cancer Invest; 2004; 22 Suppl 2():29-44. PubMed ID: 15573743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational agents for epithelial ovarian cancer.
    Muggia F; Kosloff R
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal treatment for platinum-sensitive recurrent ovarian cancer.
    Monk BJ
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):674-676. PubMed ID: 28949936
    [No Abstract]   [Full Text] [Related]  

  • 11. Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
    Poveda A; Marth C
    Future Oncol; 2017 Oct; 13(23s):11-16. PubMed ID: 29020823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of randomized trials in recurrent disease.
    Pujade-Lauraine E; Alexandre J
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii61-viii64. PubMed ID: 22180404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment and clinical trials in ovarian cancer.
    Han LY; Kipps E; Kaye SB
    Expert Opin Investig Drugs; 2010 Apr; 19(4):521-34. PubMed ID: 20367193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line treatment of first relapse recurrent ovarian cancer.
    Chua TC; Liauw W; Robertson G; Morris DL
    Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
    Baumann KH; Wagner U; du Bois A
    Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy in epithelial ovarian cancer.
    Wang J; Li AJ; Karlan BY
    Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer: diagnostic, biological and prognostic aspects.
    Davidson B; Tropé CG
    Womens Health (Lond); 2014 Sep; 10(5):519-33. PubMed ID: 25335543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.
    Liu J; Matulonis U
    J Natl Compr Canc Netw; 2006 Oct; 4(9):947-53. PubMed ID: 17020671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.